Highlight Therapeutics
PrivateLast Round
Growth Equity
Sep 16, 2025
Total Funding Raised
$44.67M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Highlight Therapeutics is a biopharmaceutical company that develops RNA-based immuno-oncology therapies designed to stimulate the immune system and enhance anti-tumor responses.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Highlight Therapeutics Comparables
Compare Highlight Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immunophotonics | 81% | |
| Lytix Biopharma AS | 77% | |
| Regeneron Pharmaceuticals | 76% |
Highlight Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Sep 16, 2025 | ||||
| Series B | Feb 5, 2021 |
Key People
Founding team and executive leadership
Highlight Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Advent Life Sciences | Series B |
| GED Capital | Growth Equity |
| Buenavista Equity Partners | Growth Equity |
| Center for Technological Development and Innovation | Series B |
| Columbus Venture Partners | Growth Equity, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 295% MoM, from 259 to 1K.
- Sep 16, 2025
$18M raised in a VC Round.
Highlight Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Highlight Therapeutics's valuation, stock price, and market status.
Is Highlight Therapeutics a public or private company?
Highlight Therapeutics is a private company.
What is the current stock price of Highlight Therapeutics?
Highlight Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Highlight Therapeutics worth (valuation)?
Valuation information for Highlight Therapeutics is not publicly available.
Can I buy Highlight Therapeutics stock?
Highlight Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Highlight Therapeutics's last funding round?
Highlight Therapeutics's most recent funding round was Growth Equity on September 16, 2025.
Who are the main investors in Highlight Therapeutics?
Key investors in Highlight Therapeutics include Advent Life Sciences, GED Capital, Buenavista Equity Partners, Columbus Venture Partners.
Will Highlight Therapeutics IPO soon?
No public IPO plans have been announced for Highlight Therapeutics.
How can I track Highlight Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Highlight Therapeutics's secondary market activity and sign up for updates.